The H1 2026 Non-Dilutive Funding Report

Non-dilutive funding hit record volumes in H1 2026, with US venture debt running at $49.6B cumulative through Q3 2025 and AI startups absorbing a third of all dollars deployed. This report covers what venture debt, revenue-based financing, and startup grants actually cost in 2026, who qualifies at each stage, and the decision framework for when each beats giving up 19% to a Series A.

• The 2026 non-dilutive funding menu at a glance
• Venture debt 2026: pricing, volume, who qualifies
• Revenue-based financing: the AI underwriting wave
• Startup grants 2026: SBIR, NSF, Horizon Europe
• RBF vs venture debt vs grants: when each beats equity
• How to raise non-dilutive capital this quarter
• When non-dilutive funding becomes a trap
• FAQ

The post-Fed-rate-cuts environment has reshaped non-dilutive funding in ways that the May 2026 startup blogs have not caught up to. US venture debt volume hit $49.6B across 674 deals through Q3 2025, the highest cumulative volume in the PitchBook dataset, and Q1 2026 median late-stage venture debt deals reached $10.8M (PitchBook News, Apr 2026). AI startups now absorb more than a third of debt dollars, and early-stage companies (not just Series B and C) capture roughly another third.

At the same time, seed and Series A founders are giving up 19 to 20% of their company per round at Carta's reported median post-money of $24M (seed) and $78.7M (Series A) (Carta, Mar 2026). Every non-dilutive dollar at those stages is worth materially more than the headline rate implies. This report is the H1 2026 menu: what venture debt costs now, where revenue-based financing has expanded, which grants still pay, and the stage-by-stage decision framework for when each option beats raising another priced round.

The 2026 non-dilutive funding menu at a glance

Five categories of non-dilutive funding are realistically accessible to early-stage startups in H1 2026. The table maps each to the stage that can raise it, typical ticket size, real cost, and the use case it fits.

Pick by stage and revenue profile, not by what is trending in your founder Slack. The rest of this report breaks each row down with 2026 data and a stage-mapped decision rule.

Venture debt 2026: pricing, volume, who qualifies

Venture debt 2026 is bigger, cheaper, and accessible earlier than at any point in the last decade. Through Q3 2025, US venture debt reached $49.6B in deal value across 674 deals, the highest cumulative volume in the PitchBook dataset (PitchBook–NVCA Q3 2025 Venture Monitor). Q1 2026 pushed median late-stage deal size to $10.8M, a decade high (PitchBook News, Apr 24, 2026).

The composition shift matters more than the volume. AI startups absorbed over a third of 2025 venture debt dollars (PitchBook News, Jul 2025), pulled in by GPU capex demand that equity rounds alone could not finance fast enough. At the same time, early-stage companies (post-seed and Series A) captured roughly another third of all dollars in 2025, contradicting the prior "venture debt is a Series B/C product" rule (PitchBook News, Jul 17, 2025).

Average deal sizes climbed in lockstep. SVB reported the YTD 2024 average US venture debt deal size at $46M (excluding CoreWeave's $7.5B May 2024 raise), up 125% from $20.4M in 2020 (Silicon Valley Bank, Dec 2024). That growth has continued into H1 2026.

The pricing math now favors debt at Series A and beyond. A typical 2026 venture debt facility runs SOFR plus 600 to 900 basis points with warrant coverage of 0.10 to 0.25% of fully-diluted equity per $1M drawn (Stifel Bank). Compare that to Carta's reported median seed dilution of 19 to 20% per round (Carta, Mar 2026): $1M of equity at the seed costs roughly 4 to 5 points of the cap table, versus 0.10 to 0.25 points for the same dollar of debt.

✅ Good: raise $3M of venture debt 60 days after closing a $15M Series A, drawn over 18 months, used to fund GPU spend and a sales hire. Warrant dilution stays under 1% and the SOFR floor protects you on rates.

❌ Bad: wait until you have six months of runway and try to raise venture debt against a stale equity round. Lenders price the facility against fresh capital, and the term sheet will come back with covenants you cannot live with.

Who qualifies in H1 2026. SVB's public guidance still says venture debt is "generally not available to seed-stage companies" because lenders underwrite to the equity sponsor and the round behind the borrower (SVB, Dec 2024). PitchBook's 2025 reality check is that early-stage startups still got a third of the dollars, but those startups raised on the back of strong A rounds with brand-name leads, not on pre-seed traction. If you do not have an institutional VC equity round closed, do not assume you qualify.

European founders should not skip this section. Atomico's State of European Tech 2025 reports $4.5B of European venture debt raised by mid-2025 after a record 2024, expanding the lender list well beyond the US and the SVB UK successor entity (HSBC Innovation Banking, Nov 2025). Active 2026 names include HSBC Innovation Banking, Bootstrap Europe, Kreos Capital, and Claret Capital Partners.

Revenue-based financing: the AI underwriting wave

Revenue-based financing has expanded faster than any other non-dilutive instrument in 2025 to 2026, driven by AI-powered underwriting that approves a facility in 72 hours. RBF lenders advance capital against future revenue and collect a fixed percentage of monthly receipts until a multiple (typically 1.1x to 1.5x) is paid back. The result: no warrants, no equity dilution, no board observers, no covenants.

RBF works for predictable recurring revenue, not for everyone. SaaS, e-commerce, marketplaces with stable take rates, and subscription B2C are the sweet spot. Hardware, deep-tech, and pre-revenue R&D companies are not. The underwriter needs at least 6 months of revenue data and ideally $20K+ MRR before they can model repayment risk.

The 2026 economics. A typical RBF deal advances $50K to $5M at a 1.2x cap (you pay back $1.20 for every $1 borrowed) over 12 to 24 months. Monthly repayments take 4 to 9% of gross revenue. The effective APR works out to 15 to 30% depending on growth rate. Cheaper than equity for any business that will be worth more than 1.3x its current valuation when the facility ends, which is most healthy SaaS companies.

The AI policy framing has bled into underwriting models. a16z's policy team has argued since May 2025 that revenue-based thresholds, in regulation and capital provision, are the right competitive lever for AI startups facing GPU and compliance costs that would otherwise force premature equity rounds (a16z, May 2025). Several 2026 RBF lenders now score AI startups on inference revenue specifically, not blended MRR.

Where RBF goes wrong: founders treat the monthly revenue share as "free money" because it is non-dilutive, and ignore the cash drag. If you owe 9% of MRR and your gross margin is 60%, the RBF facility is eating 15% of your contribution margin every month. Model the cash impact on your 18-month plan before signing. Then model it again assuming flat growth.

Startup grants 2026: SBIR, NSF, Horizon Europe

Startup grants 2026 remain the only truly free non-dilutive capital, but the application cost is real. US deep-tech and healthtech founders should treat the Small Business Innovation Research (SBIR) program as the default. NIH SBIR Phase I awards run up to $323K with Phase II up to $2.15M, while NSF, DoD, and DoE Phase I awards typically cluster between $250K and $300K. The application cycle is 6 to 12 months from submission to first wire, and most agencies open two to three windows per year.

The work is non-trivial. A competitive NIH SBIR Phase I application is 30 to 50 pages of technical narrative plus budget plus commercialization plan. Founders who treat it as a checkbox lose on technical merit. Founders who hire a grant writer ($8K to $20K) or use an AI-assisted drafting workflow win at meaningfully higher rates.

EU founders have a parallel menu. Horizon Europe and the European Innovation Council (EIC) Accelerator are the headline programs. EIC Accelerator grants run €0.5M to €2.5M with an optional €0.5M to €15M equity tranche on top, capped at €17.5M total. Application timelines are similar to SBIR. Country-level programs (Innovate UK, Bpifrance, the German Federal Ministry of Economic Affairs) layer on top.

Tax credits are the easiest non-dilutive cash to overlook. US R&D tax credits return 6 to 14% of qualified research expenses. UK SME R&D relief returned up to 27% before recent reforms (now closer to 15 to 20%). These are not grants, but they show up as real cash, often within 90 days of filing.

✅ Good: SBIR Phase I for $323K applied for in parallel with closing a $2M seed round. Cash hits 9 months later as bridge to revenue. The grant work happens to be on your product roadmap anyway.

❌ Bad: deferring the seed round to "first try the grant route." If your runway depends on a 9-month uncertain process, you do not have a grant strategy, you have a wish.

RBF vs venture debt vs grants: when each beats equity

In Q4 2025, the median seed round in Carta's dataset diluted founders by 19 to 20% for a $24M post-money valuation. Every $1M of non-dilutive capital raised at that stage saves you roughly 4 to 5 percentage points of equity, worth millions at exit if the company works.

The RBF vs venture debt vs grants decision is mostly a question of stage and revenue. The framework:

• Pre-seed, pre-revenue, deep-tech IP: grants only. Venture debt lenders will not engage without an institutional equity round behind you, and RBF underwriters need revenue. SBIR, NSF, EIC Accelerator, and R&D tax credits are the entire menu.
• Seed, $0 to $20K MRR: grants plus selective RBF. Most RBF lenders will not write a check below $20K MRR, but a few (Capchase, Pipe successors, Wayflyer for e-commerce) will engage as low as $10K MRR with strong growth. Equity is still the dominant source.
• Series A, $50K+ MRR: venture debt becomes the headline non-dilutive option. RBF still works for working capital. Grants remain a bonus, not a strategy.
• Series B+, predictable revenue: venture debt is the default. A $3M to $10M facility added to a $20M to $40M Series B extends runway by 6 to 9 months at sub-1% incremental dilution.

The hard rule: if you are taking on debt, model the cash impact assuming your next round closes 6 months late. If the debt service kills you in that scenario, do not take it. Stifel's Mark Washburn et al. advise founders to draw venture debt within 60 days of an equity round closing, not when cash tightens, because the pricing is materially better and lender confidence is highest right after a fresh equity event (Stifel Bank, Dec 2025).

How to raise non-dilutive capital this quarter

The mistake most founders make: trying to raise non-dilutive funding as a substitute for an equity round that is not coming. Lenders and grant agencies both read that signal. Run the non-dilutive process in parallel with (or 30 to 60 days after) closing an equity round, not as a replacement.

• For venture debt: start the conversation with 3 to 5 lenders 30 days before you close the equity round, share the term sheet under NDA, and aim to sign the venture debt facility within 60 days of equity close. Active 2026 US names include Stifel, Hercules Capital, Trinity Capital, Horizon Technology Finance, and the SVB residual book inside First Citizens.
• For RBF: apply directly through the lender's web flow. Most underwriting now runs on connected bank, Stripe, and accounting data. A complete application takes 30 minutes and decisions come in 48 to 72 hours. The slowest part of the process is wiring instructions, not credit review.
• For grants: start 9 months before you need the cash. SBIR open dates are public, NIH cycles three times a year, NSF twice. Hire help if you have never written one before. The ROI on a $15K grant consultant against a $300K award is obvious.
• For tax credits: retroactive filing is available in the US for prior years. If your 2024 or 2025 returns did not claim R&D credits and you had qualifying expenses, file an amended return now.

Run all four workstreams in parallel if your runway and team allow. Tooling that tracks lender conversations and grant deadlines (Causo's pipeline view, or a focused Notion board) prevents the most common failure: forgetting to follow up on the grant application because the debt term sheet showed up two days earlier.

The macro tailwind helps. CB Insights reported 2025 venture funding at $469B, the highest total since 2022, with AI nearing half of all dollars (CB Insights, Jan 2026), and Q1 2026 US VC deal value alone hit $267.2B, exceeding every full-year total except 2021 and 2025 (Q1 2026 PitchBook–NVCA Venture Monitor). Lenders compete hardest for borrowers in hot equity markets.

When non-dilutive funding becomes a trap

Non-dilutive does not mean free. Three failure patterns recur in the 2025 to 2026 data.

• The covenant breach. Venture debt term sheets carry financial covenants (minimum cash balance, revenue floors, EBITDA tests) that look manageable on signing day and crush you 12 months later when the market turns. Read every covenant. Negotiate the cash-balance floor down to 6 months of operating burn, not 9 or 12.
• The RBF cash death spiral. Founders sign an RBF deal with a 7% revenue share, assume linear growth, and then growth flattens. The fixed revenue share keeps eating cash at a rate that prevents reinvestment in growth, which keeps growth flat. The way out is usually a forced equity round at a punishing valuation.
• The grant treadmill. Founders win an SBIR Phase I, spend 6 months on the deliverables, win Phase II, spend 18 months more, and realize they have not built a venture-scale company in two years; they have built a research subcontractor for a federal agency. If the grant work is not already on your product roadmap, do not take the grant.

The CB Insights 2025 macro picture sharpens the trap point. Total funding hit $469B, the highest since 2022, but the dollars concentrated in AI mega-rounds (CB Insights, Jan 2026). Non-AI companies remained capital-constrained, which is precisely the environment where non-dilutive funding is most tempting and most dangerous. Use debt and RBF as runway extenders, never as primary capital.

FAQ

Is venture debt a good idea for early-stage startups?

Yes, but only after closing an institutional equity round and only as a runway extender (not as primary capital). PitchBook's 2025 data shows early-stage companies captured roughly a third of all US venture debt funding, so the market is open, but every successful deal had a fresh Series A or B equity round behind it. Lenders price facilities against the round, not your traction.

What is revenue-based financing and how does the repayment work?

Revenue-based financing (RBF) advances cash against future revenue and collects a fixed percentage of monthly receipts (typically 4 to 9%) until a multiple (usually 1.1x to 1.5x of principal) is paid back. There is no fixed maturity date and no warrants. Payments scale up when revenue grows and slow down when it shrinks, which is the structural advantage over a term loan.

When should a startup use non-dilutive funding instead of equity?

Use non-dilutive funding when you have predictable revenue or a clear capex use of proceeds, the runway extension lets you hit a milestone that lifts your next valuation, and the debt service survives a 6-month delay in your next equity round. Use equity when the use of proceeds is product or team building with no near-term revenue offset.

Is venture debt cheaper in 2026 after the rate cuts?

Yes, marginally. Spreads have compressed from their 2023 to 2024 peak, and SOFR has come down with the Fed cuts, but the bigger 2026 effect is volume: PitchBook reports $49.6B of US venture debt deployed through Q3 2025, with median late-stage deals at $10.8M in Q1 2026. More lenders are active and competing on terms, which is the more durable advantage than the rate itself.

What is warrant coverage on a venture debt facility?

Warrant coverage is the equity option granted to the lender as part of the facility, sized as a percentage of the loan amount and struck at the valuation of the most recent priced round. A typical 2026 deal carries warrant coverage worth 0.10 to 0.25% of fully-diluted equity per $1M borrowed (Stifel data), versus the 4 to 5 percentage points of dilution that the same dollar would cost as seed equity.

Related on the hub

• The H1 2026 AI startup funding report — Related fundraising basics guide.
• The H1 2026 Pre-Seed Funding Report — Related fundraising basics guide.
• The H1 2026 Down Rounds and Recaps Report — Related fundraising basics guide.